Talphera Achieves 50% Patient Enrollment in NEPHRO-CRRT Clinical Trial
Talphera announced 50% patient enrollment of the NEPHRO-CRRT clinical trial. "Over the course of 2025, with agreement from the FDA, we implemented significant changes to the NEPHRO CRRT clinical trial, including a nearly 60% reduction in the total number of patients to be enrolled and revising other enrollment criteria. In addition, we reviewed and updated our target profile for clinical sites to focus on medical ICUs and having nephrologists as our principal investigators. These changes have yielded positive results in enrollment rates, allowing us to achieve our 50% enrollment milestone with more than 90% of the patients from our new sites," said Vince Angotti, CEO of Talphera. "We're looking forward to completing the study, and anticipate filing our PMA this year to potentially have the only FDA approved regional anticoagulant for CRRT. We continue to receive feedback from physicians- that they desperately need a better CRRT anticoagulant. In just a few weeks, we are excited to have two key experts share their deep experience with CRRT at our planned virtual investor and analyst day," continued Angotti.
